Evidence map›Paper›PMID 36395858›Full record

ArticleChest2023

Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD.

Spyridon Fortis, Pedro M Quibrera, Alejandro P Comellas, Surya P Bhatt, Donald P Tashkin, Eric A Hoffman, Gerard J Criner, MeiLan K Han, R Graham Barr, Mehrdad Arjomandi and 19 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chest, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness.American journal of respiratory and critical care medicine · 2024
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 20 institutions in 1 country.

Spyridon FortisCenter for Access & Delivery Research & Evaluation, Iowa City VA Health Care System, Iowa City, IA; Division of Pulmonary, Critical Care and Occupational Medicine, Department of Internal Medicine, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA. Electronic address: spyridon-fortis@uiowa.edu.
Pedro M QuibreraDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Alejandro P ComellasDivision of Pulmonary, Critical Care and Occupational Medicine, Department of Internal Medicine, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA.
Surya P BhattDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham VA Medical Center, Birmingham, AL.
Donald P TashkinDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA.
Eric A HoffmanDepartments of Radiology, Biomedical Engineering and Medicine, University of Iowa, Iowa City, IA.
Gerard J CrinerDepartment of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
MeiLan K HanDivision of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, MI.
R Graham BarrDepartment of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY.
Mehrdad ArjomandiDepartment of Medicine, University of California, San Francisco, CA; San Francisco Veterans Affairs Healthcare System, San Francisco, CA.
Mark B DransfieldDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham VA Medical Center, Birmingham, AL; Division of Pulmonary and Critical Care Medicine, Birmingham VA Medical Center, Birmingham, AL.
Stephen P PetersSection on Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC.
Brett A DolezalDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA.
Victor KimDepartment of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
Nirupama PutchaDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD.
Stephen I RennardDivision of Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha, NE.
Robert PaineDivision of Respiratory, Critical Care and Occupational Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, UT.
Richard E KannerDivision of Respiratory, Critical Care and Occupational Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, UT.
Jeffrey L CurtisDivision of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, MI; Medicine Service, VA Ann Arbor Healthcare System, Ann Arbor, MI.
Russell P BowlerDepartment of Medicine, National Jewish Medical and Research Center, Denver, CO.
Fernando J MartinezDepartments of Medicine and Genetic Medicine, Weill Cornell Medicine, New York, NY.
Nadia N HanselDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD.
Jerry A KrishnanDivision of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois at Chicago, Chicago, IL.
Prescott G WoodruffDepartment of Medicine, University of California, San Francisco, CA.
Igor Z BarjaktarevicDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA.
David CouperDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Wayne H AndersonDivision of Pulmonary and Critical Care Medicine, Marsico Lung Institute, University of North Carolina School of Medicine, Chapel Hill, NC.
Christopher B CooperDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA.
Subpopulations and Intermediate Outcome Measures in COPD Study Investigators
University of California, Los Angeles · USUniversity of Utah · USJohns Hopkins University · USUniversity of Iowa · USUniversity of North Carolina at Chapel Hill · USMichigan Medicine · USTemple University · USUniversity of Alabama at Birmingham · USUniversity of California, San Francisco · USColumbia University · USUniversity of Colorado Denver · USUniversity of Illinois Chicago · USUniversity of Nebraska Medical Center · USWake Forest University · USWeill Cornell Medicine · USBirmingham VA Medical Center · USIowa City VA Health Care System · USLung Institute · USSan Francisco VA Medical Center · USVA Ann Arbor Healthcare System · US

Funding

Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa A. Troester · 2001 to 2026
$36.3M
SPIROMICS II: Biological underpinnings of COPD heterogeneity and progressionU01HL137880 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOODRUFF, PRESCOTT G · 2017 to 2021
$27.9M
NRSA Training CoreTL1TR001883 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ALEX BUI, Nina Thawata Harawa · 2016 to 2026
$8.6M
SPIROMICS GIC SupportU24HL141762 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID J, O'NEAL, WANDA K · 2018 to 2022
$7.2M
Sputum Microbial Markers of Type 2-Low AsthmaR01AI129958 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HUANG, YVONNE JEAN · 2017 to 2021
$3.6M
Prediction of COPD Progression by PRMR01HL150023 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GALBAN, CRAIG J, HAN, MEILAN K · 2020 to 2023
$2.8M
Structural Determinants of Disease Progression in COPDR01HL151421 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATT, SURYA P., NAKHMANI, ARIE · 2020 to 2024
$2.6M
1/2 Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease (Tele-COPD)UG3HL155806 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATT, SURYA P. · 2021 to 2021
$1.5M
Defining Pathways in COPD Patient Oriented ResearchK24HL138188 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MeiLan K Han · 2017 to 2026
$1.2M
Mentoring Research in Precision Medicine for Lung DiseaseK24HL137013 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRESCOTT G WOODRUFF · 2017 to 2026
$1.2M
Deep Learning and Fluid Dynamics Based Phenotyping of Expiratory Central Airway CollapseR21EB027891 · NIBIB · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATT, SURYA P., RAGHAV, VRISHANK · 2019 to 2021
$599k
NCATS NIH HHS TL1 TR001883NHLBI NIH HHS HHSN268200900013CNHLBI NIH HHS HHSN268200900014CNHLBI NIH HHS HHSN268200900015CNHLBI NIH HHS HHSN268200900016CNHLBI NIH HHS HHSN268200900017CNHLBI NIH HHS HHSN268200900018CNHLBI NIH HHS HHSN268200900019CNHLBI NIH HHS HHSN268200900020CNHLBI NIH HHS K24 HL137013NHLBI NIH HHS K24 HL138188NHLBI NIH HHS K24 HL140108NHLBI NIH HHS R01 HL150023NHLBI NIH HHS R01 HL151421NHLBI NIH HHS R21 HL153700NHLBI NIH HHS U01 HL137880NHLBI NIH HHS U24 HL141762NHLBI NIH HHS UG3 HL155806NIAID NIH HHS R01 AI129958NIBIB NIH HHS R21 EB027891NIEHS NIH HHS P30 ES005605NIEHS NIH HHS P30 ES010126
6 · The paper itself

Abstract

backgroundBronchodilator responsiveness (BDR) in obstructive lung disease varies over time and may be associated with distinct clinical features. RESEARCH QUESTION: Is consistent BDR over time (always present) differentially associated with obstructive lung disease features relative to inconsistent (sometimes present) or never (never present) BDR in tobacco-exposed people with or without COPD? STUDY DESIGN AND

methodsWe retrospectively analyzed data from 2,269 tobacco-exposed participants in the Subpopulations and Intermediate Outcome Measures in COPD Study with or without COPD. We used various BDR definitions: change of ≥ 200 mL and ≥ 12% in FEV

resultsBoth consistent and inconsistent ATS-BDR were associated with asthma history and greater small airways disease (%parametric response mapping functional small airways disease) relative to never ATS-BDR in participants with GOLD stage 0 disease and the entire cohort. We observed similar findings using FEV

interpretationDemonstration of BDR, even once, describes an obstructive lung disease phenotype with a history of asthma and greater small airways disease. Consistent demonstration of BDR indicated a high risk of lung function decline over time in the entire cohort and was associated with higher risk of progression to COPD in patients with GOLD stage 0 disease.

Indexed as

AsthmaPulmonary Disease, Chronic ObstructiveBronchodilator AgentsForced Expiratory VolumeHumansNicotianaRetrospective StudiesVital CapacityBronchodilator Agentsbronchodilatorbronchodilator responsebronchodilator responsivenessbronchodilator reversibilityCOPD

Identifiers

PMID36395858
PMCPMC9993341
OpenAlexW4308951287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.